Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05997030 · ClinicalTrials.gov registry record · NA
Low-Intensity Focused Ultrasound (LIFU) Neuromodulation
A NA study of Alzheimer Disease, sponsored by Ali Rezai.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05997030: Recruiting NA study of Alzheimer Disease, sponsored by Ali Rezai.
NCT05997030 is a NA study of Alzheimer Disease that is actively recruiting participants, run by Ali Rezai. The registered enrollment target is 15 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05997030, a NA study of Alzheimer Disease, is actively recruiting participants, sponsored by Ali Rezai.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.
Primary Outcome
Safety will be assessed by recording all adverse events that are treatment related. Each Adverse Event will be documented for patterns of occurence.
Conditions Studied
Interventions
- DEVICE low intensity focused ultrasound (LIFU)
Study Locations (1)
West Virginia
- Rockefeller Neuroscience Institute at West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-10-12 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What NCT05997030 shows while recruiting
NCT05997030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which low intensity focused ultrasound (LIFU) is the first listed.
NCT05997030 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT05997030 about?
NCT05997030 is a clinical study titled "Low-Intensity Focused Ultrasound (LIFU) Neuromodulation". This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.
What is the current status of trial NCT05997030?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2023-10-12. Estimated completion is 2026-09-30.
What conditions does trial NCT05997030 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05997030?
The interventions under investigation include: low intensity focused ultrasound (LIFU) (DEVICE).
Who is sponsoring clinical trial NCT05997030?
This trial is sponsored by Ali Rezai, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05997030 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05997030's enrollment target sits among peer trials
15 279th of 306 higher than 24 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI